UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 25, 2004 __________ SIGA Technologies, Inc. ----------------------- (Exact Name of Registrant as Specified in Charter) Delaware 0-23047 13-3864870 -------- ------- ---------- (State or other Jurisdiction of (Commission File (I.R.S. Employer Incorporation or Organization) Number) Identification Number) 420 Lexington Avenue, Suite 601, New York, New York 10170 --------------------------------------------------- ----- (Address of Principal Executive Offices) (Zip Code) (212) 672-9100 -------------- (Registrant's telephone number, including area code) ITEM 7.01. Other Events and Required FD Disclosure. ---------------------------------------- On August 25, 2004, SIGA Technologies, Inc., a Delaware corporation, issued a press release pursuant to which it announced the receipt of two grants totaling approximately $12 million from the National Institutes of Health, which will be received over the next two years and will support the development of the biowarfare defense assets recently acquired from ViroPharma Incorporated. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated in this Item 7.01 by reference. ITEM 9. Financial Statements and Exhibits --------------------------------- (c) Exhibits Exhibit No. Description ----------- ----------- 99.1 Press Release dated August 25, 2004. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGA TECHNOLOGIES, INC. By: /s/ Thomas N. Konatich ---------------------- Thomas N. Konatich Chief Financial Officer Date: August 25, 2004 3 EXHIBIT INDEX ------------- Exhibit Number Description -------------- ----------- 99.1 Press Release dated August 25, 2004.